Toni K Choueiri
Toni K Choueiri is an expert in Oncology at Dana-Farber Cancer Institute (United States). As of October 2026, ScienceLeadR ranks Toni K Choueiri in the top 1% of experts worldwide for Kidney Neoplasms, Urologic Neoplasms and Carcinoma. Toni K Choueiri has authored 1,805 publications, the most recent in 2026, and is an investigator in 57 clinical trials, 4 of them ongoing. SLR score: 9,510 (community average: 125). How the SLR is computed.
LeadR Profile
Oncology
Subspecialties: Urology - Biochemistry - Nephrology
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
- Top Carcinoma key opinion leaders — ranked #2
- Top Urogenital Neoplasms key opinion leaders — ranked #4
Organizations
Career arc: 2002 - 2026
Number : 1805
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
Clinical Studies 57
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Cohort/Consortium Investigators 2
Ongoing Clinical Trials
4 ongoing trials started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| A Study of Belzutifan (MK 6482) Plus Pembrolizumab (MK 3475) Versus Placebo Plus Pembrolizumab in Participants With Clear Cell Renal Cell Carcinoma Post Nephrectomy (MK 6482 022) NCT05239728 — cells, b7-h1 antigen, lewy bodies, safety, parkinson disease, nephrectomy, tablets, carcinoma, renal cell, hypoxia, therapeutics, ligands, cell death, carcinoma, endothelial pas domain-containing protein 1 | Phase 3 | Active not recruiting | 2022 |
| A Study of NDI 1150 101 in Patients With Solid Tumors NCT05128487 — cells, lung, safety, esophagogastric junction, neoplasms, adenocarcinoma, carcinoma, non-small-cell lung, kidney, carcinoma, renal cell, capsules, lung neoplasms, small cell lung carcinoma, maximum tolerated dose, kidney neoplasms, pharmacokinetics, carcinoma | Phase 1/Phase 2 | Active not recruiting | 2021 |
| A Study of Pembrolizumab (MK 3475) in Combination With Belzutifan (MK 6482) and Lenvatinib (MK 7902) or Pembrolizumab Quavonlimab (MK 1308A) in Combination With Lenvatinib Versus Pembrolizumab and Lenvatinib for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK 6482 012) NCT04736706 — cells, b7-h1 antigen, lewy bodies, safety, parkinson disease, tablets, carcinoma, renal cell, respect, capsules, hypoxia, therapeutics, ligands, cell death, carcinoma, endothelial pas domain-containing protein 1 | Phase 3 | Active not recruiting | 2021 |
| Sacituzumab Govitecan Plus EV in Metastatic UC NCT04724018 — urinary bladder, carcinoma, transitional cell, urinary bladder neoplasms, cells, kidney pelvis, pharmaceutical preparations, ureter, neoplasms, immunotherapy, infusions, intravenous, carcinoma | Phase 1/Phase 2 | Recruiting | 2021 |
LeadR Networks
Main global connection map